Posted On: 01/10/2016 2:51:50 PM
Post# of 94266
Gilead Ends a Phase 2 Study for Antibody
Source: Dow Jones News
Gilead Sciences Inc. is ending a Phase 2 study of simtuzumab in patients with idiopathic pulmonary fibrosis, as the study hasn't shown evidence of a treatment benefit.
The biopharmaceutical company said Phase 2 studies of the antibody simtuzumab in patients with nonalcoholic steatohepatitis and primary sclerosing cholangitis are continuing.
In September 2014, Gilead said simtuzumab didn't provide a clinical benefit in advanced pancreatic-cancer patients.
Simtuzumab, once known as AB0024 and later called GS-6624, was the lead product of Arresto Biosciences, which Gilead purchased in January 2011 for $225 million.
Earlier on Tuesday, Gilead said two Phase 3 trials evaluating tenofovir alafenamide as a hepatitis treatment met their primary objectives. Based on the results, Gilead plans U.S. and European regulatory filings in the first quarter of 2016.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 05, 2016 19:35 ET (00:35 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Source: Dow Jones News
Gilead Sciences Inc. is ending a Phase 2 study of simtuzumab in patients with idiopathic pulmonary fibrosis, as the study hasn't shown evidence of a treatment benefit.
The biopharmaceutical company said Phase 2 studies of the antibody simtuzumab in patients with nonalcoholic steatohepatitis and primary sclerosing cholangitis are continuing.
In September 2014, Gilead said simtuzumab didn't provide a clinical benefit in advanced pancreatic-cancer patients.
Simtuzumab, once known as AB0024 and later called GS-6624, was the lead product of Arresto Biosciences, which Gilead purchased in January 2011 for $225 million.
Earlier on Tuesday, Gilead said two Phase 3 trials evaluating tenofovir alafenamide as a hepatitis treatment met their primary objectives. Based on the results, Gilead plans U.S. and European regulatory filings in the first quarter of 2016.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 05, 2016 19:35 ET (00:35 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
(0)
(0)
